Outlook Therapeutics Files 8-K on Financials
Ticker: OTLK · Form: 8-K · Filed: May 15, 2025 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | May 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
OTLK filed an 8-K on 5/15/25 detailing financial results.
AI Summary
Outlook Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Iselin, New Jersey.
Why It Matters
This filing provides investors with an update on the company's financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
- Iselin, New Jersey (location) — Principal executive offices
- Oncobiologics, Inc. (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Outlook Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2025.
Where are Outlook Therapeutics, Inc.'s principal executive offices located?
Outlook Therapeutics, Inc.'s principal executive offices are located at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830.
What was Outlook Therapeutics, Inc. formerly known as?
Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc.
What is the company's fiscal year end?
The company's fiscal year end is September 30 (0930).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Outlook Therapeutics, Inc. (OTLK).